To all of the arrogant Management team, this is called Karma. Of course there will now be downsizing and your heads will be on the chopping block. Sit back and reflect on how many people left or were forced to leave because of your decisions or lack of decisions. Don't even think about trying to find another job in the MS market or even Neurology. Karma will bite you. Unfortunately the KAMS will be the losers. Why do you think they added SAMs? Time to cut down the KAMS in the lower tier accounts. The company drunk will try to spin this on a conference call. He will say "hang if there, we will meet with the FDA again". It's over. Will you diehard protectors of EMD Serono finally admit the company is a complete failure? Tell me why you would continue to work for a loser company.
At the end of the day its a job that pays pretty well and I dont know if you checked but the economy sucks and most other companies have the same issues. Some are managed better but all have problems. It is what it is. You have issues btw. You left be happy and get over it
Time to file the discrimination lawsuits. You have been waiting for years and was hoping for the best. It's over. Before you are laid off, file now. Why have you not been promoted? All boys club? Race? Gender? Make money while there is still time.
Ernesto NEVER would have lead us down the road to failure. We all cared and worked toward success...that's why Serono was worth $16 billion and EMD Serono is worthless. Everyone with any heart or vision is gone only greed and indifference remain. Sad to say. Sad to see.
This was never going to be a big seller. The molecule goes back to 1994 - so it couldn't have much patent life. In fact Cladribine was orginally desginated as an orphan drug for MS. I seem to recall that it has been a problem drug since day 1.
Does the company think we are all stupid?The conference call was pure spin.We all know Clad is dead in the water so just admit it.I am worried about layoffs in the Summer.
Some middle management pointed out time and time the shortcomings of the cladribine program but the erogant management team wouldn't listen. Some good people left or were pushed out because they were "not onboard"...unfortunately this is the same story for many places outthere .... Yes there is karma and I am glad the FDA saw through the bull and stopped this drug and company from selling crap to patients... Feredoon and his entourage need to go if Merck want to get back some of the $16b they invested in this worthless company... Ernesto is a real shrewd businessman, good for him!
"Trying to make do with less data, though, has failed to impress the drug agencies so far. Novartis won the regulatory race in part because its researchers set out early on to probe the risks Gilenya posed to patients. Novartis ran multiple late-stage trials; Merck ran one. As a result, Merck KGaA never sufficiently responded to regulators concerned about the effects of immunosuppression on patients. And regulators in Europe rejected the cladribine application last year. In the U.S. the German company has faced a series of delays, starting with the FDA's refusal to accept its original application. Novartis now has months more to capitalize on its savvy development strategy. Gilenya will likely head for blockbuster status as it competes with injectables like Rebif and betaseron, leaving Merck KGaA to do R&D work that should have been completed long ago." Who is running this place?
Many years ago Serono management outlined their grandiose plan to get cladribine quickly on the market because the efficacy was so easy to demonstrate. They planned to use ancient i.v. therapy data from the 1990s to support the application. They completely ignored the hematology literature about neoplastic risks. They did not do a head to head trial. They only did one trial. They tested the drug in a mild population, not the refractory population. They did not address risks in the protocol. Early on they had a death due to infection and had to scramble to try to improve the safety factors in the trial. Then, instead of following profoundly immunosuppressed patients carefully, they sent them all out on their way and failed to do a planned data collection. Cancers were a tremendous excess in the treatment arm. Then they tried to have their investigators spin this that it was a fluke and could not be due to medication. Bravo to the regulators for seeing through the crap.
Name a Serono plan that worked. Even Rebif did not live up to its potential. Failures and poor planning are the norm at Serono. Although the senior sales management team is not to blame for clad, they need to be held accountable for sales targets falling short. The way they come close to meeting wall street targets is by raising prices
Is Serono still being sued for the rep overtime? Where do we go to sign up? Or is it automatic? May as well get paid if they have us shackled with the "Agreement"!
So what is the marketing team doing now? Still riding bikes, Carole does look great in spandex! Same leadership....same results
Luckily we have received the CEO Gold Standard Accreditation. That should really help save us now that Clad is dead. Where is the leadership team? Fereydoun = FereyDOOM.
